The chief scientific officer at 23andMe is leaving his role at the consumer genetics company, four years after his arrival helped energize its move toward drug discovery.

Richard Scheller, a Genentech veteran, has joined the Palo Alto, Calif.-based BridgeBio (BBIO) as chairman of research and development, according to Securities and Exchange Commission filings. Scheller remains on 23andMe’s board of directors. 

Continue to STAT Plus to read the full story…

Source link